Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.53 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | GFER | P55789 | 2/20 | 0.47 |
| ▸ | UQCRB | P14927 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | FBP1 | P09467 | 1/20 | 0.45 |
| ▸ | IKBKB | O14920 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3945167 | 0.91 | BRD4 (0.61) | BRD4SERPINE1PTPN5MEN1KMT2A | |
| SCHEMBL3943963 | 0.90 | BRD4 (0.52) | BRD4SERPINE1PTPN5MEN1KMT2A | |
| SCHEMBL3945225 | 0.90 | BRD4 (0.54) | BRD4SERPINE1PTPN5MEN1KMT2A | |
| SCHEMBL4934791 | 0.90 | UQCRB (0.57) | BRD4SERPINE1PTPN5MEN1KMT2A | |
| SCHEMBL3950142 | 0.89 | BRD4 (0.53) | BRD4SERPINE1PTPN5MEN1KMT2A | |
| Dimethylamine SCHEMBL4931369 | 0.89 | BRD4 (0.59) | BRD4SERPINE1PTPN5MEN1KMT2A | |
| SCHEMBL4927787 | 0.88 | BRD4 (0.52) | BRD4SERPINE1PTPN5MEN1KMT2A | |
| SCHEMBL4927088 | 0.88 | BRD4 (0.50) | BRD4SERPINE1PTPN5MEN1KMT2A | |
| SCHEMBL4926342 | 0.88 | BRD4 (0.52) | BRD4SERPINE1PTPN5MEN1KMT2A | |
| SCHEMBL4929144 | 0.88 | HIF1A (0.52) | BRD4SERPINE1MEN1KMT2AGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1802572-B1 | INDOL DERIVATIVES AS INHIBITORS OF SOLUBLE ADENYLYL CYCLASE | BAYER SCHERING PHARMA AG (DE) | 2009-04-22 | — | — | EP | disclosed |
| US-20080004268-A1 | INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | NGUYEN DUY | 2008-01-03 | — | — | US | disclosed |
| EP-1802572-A1 | INDOL DERIVATIVES AS INHIBITORS OF SOLUBLE ADENYLYL CYCLASE | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-07-04 | — | — | EP | disclosed |
| US-20060074084-A1 | Inhibitors of soluble adenylate cyclase | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-04-06 | — | — | US | disclosed |
| WO-2006032541-A1 | INDOL DERIVATIVES AS INHIBITORS OF SOLUBLE ADENYLYL CYCLASE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004268-A1 | INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | ADCY1, ADCY2, ADCY5 | BRD4 3928/4885SERPINE1 688/4885PTPN5 1567/4885 |
| US-20060074084-A1 | Inhibitors of soluble adenylate cyclase | ADCY1, ADCY2, ADCY5 | BRD4 3928/4885SERPINE1 688/4885PTPN5 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.